Sorafenib for advanced hepatocellular carcinoma (HCC): Impact of rationing in the United Kingdom

被引：1
|
作者：
Palmer, D. H. [1 ]
Hussain, S. A. [1 ]
Smith, A. J. [1 ]
Hull, D. [1 ]
Johnson, P. J. [1 ]
机构：
[1] Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e14516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14516
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
    Palmer, D. H.
    Hussain, S. A.
    Smith, A. J.
    Hargreaves, S.
    Ma, Y. T.
    Hull, D.
    Johnson, P. J.
    Ross, P. J.
    BRITISH JOURNAL OF CANCER, 2013, 109 (04) : 888 - 890
  • [2] Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
    D H Palmer
    S A Hussain
    A J Smith
    S Hargreaves
    Y T Ma
    D Hull
    P J Johnson
    P J Ross
    British Journal of Cancer, 2013, 109 : 888 - 890
  • [3] SORAFENIB FOR ADVANCED HEPATOCELLULAR CARCINOMA (HCC): IMPACT OF RATIONING IN THE UNITED KINGDOM
    Smith, A.
    Hussain, S.
    Hull, D.
    Johnson, P.
    Palmer, D.
    ANNALS OF ONCOLOGY, 2010, 21 : 95 - 95
  • [4] Sorafenib in advanced hepatocellular carcinoma (HCC) : Ascites as prognostic factor
    Koch, S.
    Niederle, I.
    Gamstaetter, T.
    Schuchmann, M.
    Galle, P.
    Woerns, M.
    Weinmann, A.
    INTERNIST, 2013, 54 (06): : 745 - 745
  • [5] Sorafenib in advanced hepatocellular carcinoma (HCC) : Ascites as prognostic factor
    Koch, S.
    Niederle, I.
    Gamstaetter, T.
    Schuchmann, M.
    Galle, P.
    Woerns, M.
    Weinmann, A.
    INTERNIST, 2013, 54 : 10 - 10
  • [6] A Phase II Study of Bavituximab and Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
    Yopp, A.
    Zhu, H.
    Mansour, J.
    Singal, A.
    Arriaga, Y.
    Beg, S.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S34 - S35
  • [7] SORAFENIB TREATMENT FOR HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH ADVANCED LIVER DISEASE
    Alves, Rogerio C.
    Alves, Daniele E.
    Guz, Betty
    Viana, Monica V.
    Harriz, Michelle C.
    Matos, Carla A.
    Terrabuio, Deborah
    Chagas, Aline
    Moutinho, Renata D.
    Taddeo, Eliane F.
    Duarte, Kelly C.
    Oliveira, George P.
    Ribeirol, Juliana M.
    Kondo, Mario
    Gampel, Otavio
    Poletti, Paula
    HEPATOLOGY, 2010, 52 (04) : 1193A - 1193A
  • [8] Outcomes and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC)
    Ziogas, Dimitrios
    Thillai, Kiruthikah
    Korantzis, Ippokratis
    Chowdhury, M. H. Ruhe
    Papadatos-Pastos, Dionysios
    Suddle, Abid
    O'Grady, John
    Heaton, Nigel
    Ross, Paul J.
    Sarker, Debashis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [9] Outcomes and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC)
    Ziogas, Dimitris
    Thillai, Kiruthikah
    Papadatos-Pastos, Dionysios
    Chowdhury, Mahfuja Hussain Ruhe
    Korantzis, Ippokratis
    Manickavasagar, Thubeena
    Suddle, Abid
    O'Grady, John
    Heaton, Nigel
    Ross, Paul J.
    Sarker, Debashis
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] A phase II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC).
    Yopp, Adam Charles
    Singal, Amit G.
    Arriaga, Yull Edwin
    Verma, Udit N.
    Shan, Joseph
    Kallinteris, Nikoletta
    Beg, Muhammad Shaalan
    Mansour, John C.
    Zhu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
12345